


Supplemental Figure S1. Participant flow



AKDN Alberta Kidney Disease Network

Supplemental Table S1. Glomerular filtration rate overall and by age and gender

Population	Overall	Age, years				Gender	
		<65	≥65	65-74	≥75	Female	Male
Overall	260,903	139,568	121,335	66,472	54,863	121,129	139,774
eGFR, mL/min*1.73m² ≥90	96,902 (37.1)	83,443 (59.8)	13,459 (11.1)	12,272 (18.5)	1,187 (2.2)	46,350 (38.3)	50,552 (36.2)
60-89	112,705 (43.2)	47,391 (34.0)	65,314 (53.8)	38,862 (58.5)	26,452 (48.2)	49,237 (40.6)	63,468 (45.4)
45-59	29,069 (11.1)	5,140 (3.7)	23,929 (19.7)	9,633 (14.5)	14,296 (26.1)	14,336 (11.8)	14,733 (10.5)
30-44	14,698 (5.6)	1,871 (1.3)	12,827 (10.6)	3,792 (5.7)	9,035 (16.5)	7,580 (6.3)	7,118 (5.1)
<30	7,529 (2.9)	1,723 (1.2)	5,806 (4.8)	1,913 (2.9)	3,893 (7.1)	3,626 (3.0)	3,903 (2.8)

eGFR estimated glomerular filtration rate N (%) are reported

Supplemental Table S2. Anti-hyperglycemic class by CKD stage (monotherapy only)

Anti-hyperglycemic class	Overall	No CKD, eGFR			CKD stages				
		>60	>90	60-89	1	2	3a	3b	4/5
Overall	260,903	174,920	81,383	93,537	15,519	19,168	29,069	14,698	7,529
DPP-4 inhibitor	553 (0.2)	296 (0.2)	87 (0.1)	209 (0.2)	11 (0.1)	30 (0.2)	85 (0.3)	65 (0.4)	66 (0.9)
GLP-1 receptor agonist	202 (0.1)	164 (0.1)	86 (0.1)	78 (0.1)	9 (0.1)	3 (0.0)	19 (0.1)	6 (0.0)	1 (0.0)
Insulin	9,087 (3.5)	5,057 (2.9)	3,022 (3.7)	2,035 (2.2)	555 (3.6)	653 (3.4)	878 (3.0)	837 (5.7)	1,107 (14.7)
Biguanide (metformin)	50,889 (19.5)	36,152 (20.7)	15,555 (19.1)	20,597 (22.0)	2,701 (17.4)	3,886 (20.3)	5,668 (19.5)	2,138 (14.5)	344 (4.6)
SGLT2 inhibitor	319 (0.1)	267 (0.2)	134 (0.2)	133 (0.1)	26 (0.2)	7 (0.0)	15 (0.1)	4 (0.0)	0 (0.0)
Sulfonylureas	1,779 (0.7)	858 (0.5)	275 (0.3)	583 (0.6)	53 (0.3)	129 (0.7)	292 (1.0)	267 (1.8)	180 (2.4)
Meglitinide (repaglinide)	561 (0.2)	156 (0.2)	44 (0.1)	112 (0.2)	6 (0.0)	19 (0.1)	58 (0.2)	102 (0.7)	220 (2.9)
Other	212 (0.1)	130 (0.1)	41 (0.1)	89 (0.1)	6 (0.0)	12 (0.1)	31 (0.1)	20 (0.1)	13 (0.2)

CKD chronic kidney disease, DPP-4 Dipeptidyl peptidase-4, eGFR estimated glomerular filtration rate, GLP-1 Glucagon-like peptide-1, SGLT2 Sodium-glucose linked transporter 2 N (%) are reported

Supplemental Table S3. Anti-hyperglycemic class by CKD stage

Anti-hyperglycemic class	Overall	No CKD, eGFR			CKD stages				
		>60	>90	60-89	1	2	3a	3b	4/5
Overall	260,903	174,920	81,383	93,537	15,519	19,168	29,069	14,698	7,529
DPP-4 inhibitor	30,884 (11.8)	18,910 (10.8)	9,156 (11.3)	9,754 (10.4)	2,675 (17.2)	3,176 (16.6)	3,513 (12.1)	1,875 (12.8)	735 (9.8)
GLP-1 receptor agonist	6,322 (2.4)	4,405 (2.5)	2,576 (3.2)	1,829 (2.0)	698 (4.5)	533 (2.8)	465 (1.6)	182 (1.2)	39 (0.5)
Insulin	39,746 (15.2)	21,436 (12.3)	10,831 (13.3)	10,605 (11.3)	3,385 (21.8)	4,381 (22.9)	5,021 (17.3)	3,285 (22.3)	2,238 (29.7)
Biguanide (metformin)	125,205 (48.0)	81,395 (46.5)	37,423 (46.0)	43,972 (47.0)	9,317 (60.0)	11,975 (62.5)	14,587 (50.2)	6,501 (44.2)	1,430 (19.0)
SGLT2 inhibitor	19,808 (7.6)	13,623 (7.8)	7,271 (8.9)	6,352 (6.8)	2,178 (14.0)	2,022 (10.5)	1,538 (5.3)	397 (2.7)	50 (0.7)
Sulfonylureas	37,491 (14.4)	22,237 (12.7)	10,217 (12.6)	12,020 (12.9)	3,146 (20.3)	4,004 (20.9)	4,735 (16.3)	2,509 (17.1)	860 (11.4)
Meglitinide (repaglinide)	9,732 (3.7)	4,818 (5.3)	1,982 (2.4)	2,836 (3.0)	682 (4.4)	997 (5.2)	1,347 (4.6)	1,038 (7.1)	850 (11.3)
Combination	79,400 (30.4)	47,745 (27.3)	22,961 (28.2)	24,784 (26.5)	6,894 (44.4)	8,449 (44.1)	9,558 (32.9)	4,980 (33.9)	1,774 (23.6)
Other	5,030 (1.9)	3,005 (1.7)	1,208 (1.5)	1,797 (1.9)	297 (1.9)	505 (2.6)	712 (2.4)	374 (2.5)	137 (1.8)

CKD chronic kidney disease, DPP-4 Dipeptidyl peptidase-4, eGFR estimated glomerular filtration rate, GLP-1 Glucagon-like peptide-1, SGLT2 Sodium-glucose linked transporter 2 N (%) are reported

Supplemental Table S4. Anti-hyperglycemic class by prior CVD

Anti-hyperglycemic class	Prior CVD			
	CVD	CAD	PAD	Stroke/TIA
N	58,595	27,395	8,772	33,733
DPP-4 inhibitor	6,524 (11.1)	3,374 (12.3)	830 (9.5)	3,337 (9.9)
GLP-1 receptor agonist	1,017 (1.7)	501 (1.8)	109 (1.2)	531 (1.6)
Insulin	11,118 (19.0)	5,716 (20.9)	1,886 (21.5)	6,029 (17.9)
Biguanide (metformin)	27,868 (47.6)	14,071 (51.4)	3,506 (40.0)	15,053 (44.6)
SGLT2 inhibitor	3,679 (6.3)	1,975 (7.2)	440 (5.0)	1,818 (5.4)
Sulfonylureas	8,663 (14.8)	4,510 (16.5)	1,061 (12.1)	4,586 (13.6)
Meglitinide (repaglinide)	2,892 (4.9)	1,408 (5.1)	473 (5.4)	1,642 (4.9)
Combination	18,545 (31.6)	9,648 (35.2)	2,466 (28.1)	9,822 (29.1)
Other	1,002 (1.7)	417 (1.5)	136 (1.6)	590 (1.7)

DPP-4 Dipeptidyl peptidase-4, GLP-1 Glucagon-like peptide-1, A1C glycated hemoglobin, SGLT2 Sodium-glucose linked transporter 2, T2DM type 2 diabetes mellitus N (%) are reported

